Cargando…
Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma
Phosphoinositide 3-kinase (PI3K) and Myc are known to cooperate in promoting the survival and growth of a variety of B-cell lymphomas. While currently there are no small molecule inhibitors of Myc protein, histone deacetylase (HDAC) inhibitors have been shown to reduce levels of Myc protein by suppr...
Autores principales: | Mondello, Patrizia, Derenzini, Enrico, Asgari, Zahra, Philip, John, Brea, Elliott J., Seshan, Venkatraman, Hendrickson, Ronald C., de Stanchina, Elisa, Scheinberg, David A., Younes, Anas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355158/ https://www.ncbi.nlm.nih.gov/pubmed/28147336 http://dx.doi.org/10.18632/oncotarget.14876 |
Ejemplares similares
-
NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death
por: Liu, Yuxuan, et al.
Publicado: (2018) -
Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010) -
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma
por: Okabe, Seiichi, et al.
Publicado: (2021) -
Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances
por: Derenzini, Enrico, et al.
Publicado: (2011) -
ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors
por: Portelinha, Ana, et al.
Publicado: (2021)